Central Nervous System Hematopoietic and Lymphoid Cell Neoplasm

Observed

← altered in cohorts of

PIM1

33 / 86 cases (38 %) · ssm · pcnsl_msk_2024

—

Observed

← altered in cohorts of

CD79B

20 / 86 cases (23 %) · ssm · pcnsl_msk_2024

—

Observed

← altered in cohorts of

KMT2D

20 / 86 cases (23 %) · ssm · pcnsl_msk_2024

—

Observed

Central Nervous System Hematopoietic and Lymphoid Cell Neoplasm

Central Nervous System Hematopoietic and Lymphoid Cell Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 70show all (up to 200)
→ investigated in trials for	Methotrexatesmall molecule 37 trials (15 active) · roll-up of the cancer and its descendants	—	—	Central Nervous System Hematopoietic and Lymphoid Cell Neoplasm	37	Observed	clinicaltrials	graph →
→ investigated in trials for	Rituximabmonoclonal antibody 35 trials (16 active) · roll-up of the cancer and its descendants	—	—	Central Nervous System Hematopoietic and Lymphoid Cell Neoplasm	35	Observed	clinicaltrials	graph →
→ investigated in trials for	Lenalidomidesmall molecule 15 trials (6 active) · roll-up of the cancer and its descendants	—	—	Central Nervous System Hematopoietic and Lymphoid Cell Neoplasm	15	Observed	clinicaltrials	graph →
→ investigated in trials for	Ibrutinibsmall molecule 13 trials (6 active) · roll-up of the cancer and its descendants	—	—	Central Nervous System Hematopoietic and Lymphoid Cell Neoplasm	13	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 8 trials (6 active) · roll-up of the cancer and its descendants	—	—	Central Nervous System Hematopoietic and Lymphoid Cell Neoplasm	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Temozolomidesmall molecule 8 trials (3 active) · roll-up of the cancer and its descendants	—	—	Central Nervous System Hematopoietic and Lymphoid Cell Neoplasm	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Cytarabinesmall molecule 7 trials (4 active) · roll-up of the cancer and its descendants	—	—	Central Nervous System Hematopoietic and Lymphoid Cell Neoplasm	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Dexamethasonesmall molecule 6 trials (3 active) · roll-up of the cancer and its descendants	—	—	Central Nervous System Hematopoietic and Lymphoid Cell Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Fludarabinesmall molecule 6 trials (4 active) · roll-up of the cancer and its descendants	—	—	Central Nervous System Hematopoietic and Lymphoid Cell Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 6 trials (2 active) · roll-up of the cancer and its descendants	—	—	Central Nervous System Hematopoietic and Lymphoid Cell Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Zanubrutinibsmall molecule 6 trials (3 active) · roll-up of the cancer and its descendants	—	—	Central Nervous System Hematopoietic and Lymphoid Cell Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Pemetrexedsmall molecule 5 trials (3 active) · roll-up of the cancer and its descendants	—	—	Central Nervous System Hematopoietic and Lymphoid Cell Neoplasm	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Acalabrutinibsmall molecule 4 trials (4 active) · roll-up of the cancer and its descendants	—	—	Central Nervous System Hematopoietic and Lymphoid Cell Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Etoposidesmall molecule 4 trials (0 active) · roll-up of the cancer and its descendants	—	—	Central Nervous System Hematopoietic and Lymphoid Cell Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Leucovorinsmall molecule 4 trials (2 active) · roll-up of the cancer and its descendants	—	—	Central Nervous System Hematopoietic and Lymphoid Cell Neoplasm	4	Observed	clinicaltrials	graph →

Central Nervous System Hematopoietic and Lymphoid Cell Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 70show all (up to 200)

→ investigated in trials for

Methotrexatesmall molecule

37 trials (15 active) · roll-up of the cancer and its descendants

—

Observed

Central Nervous System Hematopoietic and Lymphoid Cell Neoplasm

→ investigated in trials for

Rituximabmonoclonal antibody

35 trials (16 active) · roll-up of the cancer and its descendants

—

Observed

Central Nervous System Hematopoietic and Lymphoid Cell Neoplasm

→ investigated in trials for

Lenalidomidesmall molecule

15 trials (6 active) · roll-up of the cancer and its descendants

—

Observed

Central Nervous System Hematopoietic and Lymphoid Cell Neoplasm

→ investigated in trials for

Ibrutinibsmall molecule

13 trials (6 active) · roll-up of the cancer and its descendants

—

Observed

Central Nervous System Hematopoietic and Lymphoid Cell Neoplasm

→ investigated in trials for

Cyclophosphamidesmall molecule

8 trials (6 active) · roll-up of the cancer and its descendants

—

Observed

Central Nervous System Hematopoietic and Lymphoid Cell Neoplasm

→ investigated in trials for

Temozolomidesmall molecule

8 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

Central Nervous System Hematopoietic and Lymphoid Cell Neoplasm

→ investigated in trials for

Cytarabinesmall molecule

7 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

Central Nervous System Hematopoietic and Lymphoid Cell Neoplasm

→ investigated in trials for

Dexamethasonesmall molecule

6 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

Central Nervous System Hematopoietic and Lymphoid Cell Neoplasm

→ investigated in trials for

Fludarabinesmall molecule

6 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

Central Nervous System Hematopoietic and Lymphoid Cell Neoplasm

→ investigated in trials for

Nivolumabmonoclonal antibody

6 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

Central Nervous System Hematopoietic and Lymphoid Cell Neoplasm

→ investigated in trials for

Zanubrutinibsmall molecule

6 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

Central Nervous System Hematopoietic and Lymphoid Cell Neoplasm

→ investigated in trials for

Pemetrexedsmall molecule

5 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

Central Nervous System Hematopoietic and Lymphoid Cell Neoplasm

→ investigated in trials for

Acalabrutinibsmall molecule

4 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

Central Nervous System Hematopoietic and Lymphoid Cell Neoplasm

→ investigated in trials for

Etoposidesmall molecule

4 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

Central Nervous System Hematopoietic and Lymphoid Cell Neoplasm

→ investigated in trials for

Leucovorinsmall molecule

4 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

Central Nervous System Hematopoietic and Lymphoid Cell Neoplasm studied in …STUDIED_INderived10 of 224show all (up to 200)
→ studied in	NCT07839247Phase 2 · recruiting Zanubrutinib Plus Lenalidomide for Frail Elderly Patients With Newly Diagnosed PCNSL · condition mapped ONTOLOGY_EXACT · 224 trials mapped (93 active)	—	—	Primary Central Nervous System Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07842835not yet recruiting Registry of an Integrated Longitudinal Multimodal Biospecimen Biobank for Primary CNS Lymphoma in China (CLIMB) · condition mapped ONTOLOGY_EXACT · 224 trials mapped (93 active)	—	—	Primary Central Nervous System Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06175000Phase 2 · recruiting Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response · condition mapped ONTOLOGY_EXACT · 224 trials mapped (93 active)	—	—	Primary Central Nervous System Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04688151Phase 1 · completed Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma. · condition mapped ONTOLOGY_EXACT · 224 trials mapped (93 active)	—	—	Primary Central Nervous System Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04462328Phase 1 · active not recruiting Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma · condition mapped ONTOLOGY_EXACT · 224 trials mapped (93 active)	—	—	Primary Central Nervous System Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03964090Phase 2 · active not recruiting Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) · condition mapped ONTOLOGY_EXACT · 224 trials mapped (93 active)	—	—	Central Nervous System Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04609046Phase 1 · active not recruiting Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma · condition mapped ONTOLOGY_EXACT · 224 trials mapped (93 active)	—	—	Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System	1	Observed	clinicaltrials	graph →
→ studied in	NCT02203526Phase 1 · active not recruiting Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma · condition mapped ONTOLOGY_EXACT · 224 trials mapped (93 active)	—	—	Primary Central Nervous System Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04464200Phase 1 · active not recruiting 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers · condition mapped ALIAS · 224 trials mapped (93 active)	—	—	Primary Central Nervous System Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03959085Phase 3 · recruiting Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy · condition mapped ONTOLOGY_EXACT · 224 trials mapped (93 active)	—	—	Central Nervous System Leukemia	1	Observed	clinicaltrials	graph →

Central Nervous System Hematopoietic and Lymphoid Cell Neoplasm studied in …STUDIED_INderived10 of 224show all (up to 200)

→ studied in

NCT07839247Phase 2 · recruiting

Zanubrutinib Plus Lenalidomide for Frail Elderly Patients With Newly Diagnosed PCNSL · condition mapped ONTOLOGY_EXACT · 224 trials mapped (93 active)

—

Observed

→ studied in

NCT07842835not yet recruiting

Registry of an Integrated Longitudinal Multimodal Biospecimen Biobank for Primary CNS Lymphoma in China (CLIMB) · condition mapped ONTOLOGY_EXACT · 224 trials mapped (93 active)

—

Observed

→ studied in

NCT06175000Phase 2 · recruiting

Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response · condition mapped ONTOLOGY_EXACT · 224 trials mapped (93 active)

—

Observed

→ studied in

NCT04688151Phase 1 · completed

Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma. · condition mapped ONTOLOGY_EXACT · 224 trials mapped (93 active)

—

Observed

→ studied in

NCT04462328Phase 1 · active not recruiting

Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma · condition mapped ONTOLOGY_EXACT · 224 trials mapped (93 active)

—

Observed

Central Nervous System Lymphoma

→ studied in

NCT03964090Phase 2 · active not recruiting

Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) · condition mapped ONTOLOGY_EXACT · 224 trials mapped (93 active)

—

Observed

Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System

→ studied in

NCT04609046Phase 1 · active not recruiting

Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma · condition mapped ONTOLOGY_EXACT · 224 trials mapped (93 active)

—

Observed

→ studied in

NCT02203526Phase 1 · active not recruiting

Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma · condition mapped ONTOLOGY_EXACT · 224 trials mapped (93 active)

—

Observed

→ studied in

NCT04464200Phase 1 · active not recruiting

19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers · condition mapped ALIAS · 224 trials mapped (93 active)

—

Observed

Central Nervous System Leukemia

→ studied in

NCT03959085Phase 3 · recruiting

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy · condition mapped ONTOLOGY_EXACT · 224 trials mapped (93 active)

—

Observed